Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVXNASDAQ:CRBPNASDAQ:MREONASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXABIVAX Société Anonyme$8.27+6.8%$6.23$4.77▼$14.71$524.43M0.29145,448 shs4,742 shsCRBPCorbus Pharmaceuticals$8.32+13.3%$6.67$4.64▼$61.90$100.34M3.19352,809 shs235,884 shsMREOMereo BioPharma Group$2.67+0.6%$2.27$1.58▼$5.02$426.92M0.531.11 million shs13,031 shsPRTAProthena$4.86+4.3%$8.54$4.32▼$25.42$259.98M0.11692,020 shs1.31 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXABIVAX Société Anonyme+21.89%+36.03%+7.65%-1.40%-42.58%CRBPCorbus Pharmaceuticals+13.08%+12.77%+6.55%+21.35%-82.28%MREOMereo BioPharma Group+3.92%+21.56%-0.75%+4.74%-23.08%PRTAProthena+3.65%+5.46%-43.18%-67.69%-78.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXABIVAX Société Anonyme2.569 of 5 stars3.54.00.00.02.10.80.6CRBPCorbus Pharmaceuticals4.3858 of 5 stars4.60.00.04.73.92.50.0MREOMereo BioPharma Group1.845 of 5 stars3.61.00.00.02.61.70.0PRTAProthena2.8491 of 5 stars4.21.00.00.02.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXABIVAX Société Anonyme 3.00Buy$31.00274.85% UpsideCRBPCorbus Pharmaceuticals 3.10Buy$50.88511.85% UpsideMREOMereo BioPharma Group 3.25Buy$7.71189.47% UpsidePRTAProthena 2.33Hold$31.50548.15% UpsideCurrent Analyst Ratings BreakdownLatest CRBP, ABVX, MREO, and PRTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025PRTAProthenaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform5/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.005/27/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/27/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $14.005/27/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.005/13/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$48.00 ➝ $30.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXABIVAX Société AnonymeN/AN/AN/AN/A$3.37 per shareN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/A($1.56) per shareN/AMREOMereo BioPharma Group$1M423.74N/AN/A$0.36 per share7.40PRTAProthena$137.94M1.90N/AN/A$10.46 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXABIVAX Société Anonyme-$159.90MN/A0.00N/AN/AN/AN/AN/A8/11/2025 (Estimated)CRBPCorbus Pharmaceuticals-$44.60M-$4.22N/AN/AN/AN/A-42.28%-32.92%8/5/2025 (Estimated)MREOMereo BioPharma Group-$29.47M-$0.07N/AN/AN/AN/AN/AN/A8/12/2025 (Estimated)PRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%8/14/2025 (Estimated)Latest CRBP, ABVX, MREO, and PRTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/6/2025Q1 2025CRBPCorbus Pharmaceuticals-$1.26-$1.39-$0.13-$1.39N/AN/A3/26/2025Q4 2024MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.01$72.50 millionN/A3/11/2025Q4 2024CRBPCorbus Pharmaceuticals-$1.02-$0.78+$0.24-$0.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXABIVAX Société AnonymeN/AN/AN/AN/AN/ACRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXABIVAX Société Anonyme0.483.04N/ACRBPCorbus PharmaceuticalsN/A13.8413.84MREOMereo BioPharma GroupN/A6.106.10PRTAProthenaN/A11.5211.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXABIVAX Société Anonyme47.91%CRBPCorbus Pharmaceuticals64.64%MREOMereo BioPharma Group62.83%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipABVXABIVAX Société AnonymeN/ACRBPCorbus Pharmaceuticals3.60%MREOMereo BioPharma Group5.50%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXABIVAX Société Anonyme6163.44 millionN/ANot OptionableCRBPCorbus Pharmaceuticals4012.24 million11.69 millionOptionableMREOMereo BioPharma Group40159.00 million148.74 millionOptionablePRTAProthena13053.83 million38.64 millionOptionableCRBP, ABVX, MREO, and PRTA HeadlinesRecent News About These CompaniesUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in Prothena Co. plc (NASDAQ:PRTA)June 3 at 3:58 AM | marketbeat.comAnalysts Set Prothena Co. plc (NASDAQ:PRTA) Price Target at $31.50June 3 at 2:23 AM | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of "Hold" by BrokeragesJune 1 at 3:25 AM | marketbeat.comFY2025 EPS Estimates for Prothena Cut by Chardan CapitalMay 31, 2025 | marketbeat.comHC Wainwright Has Weak Outlook for Prothena FY2027 EarningsMay 31, 2025 | americanbankingnews.comPiper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial DiscontinuationMay 30, 2025 | msn.comChardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial FailureMay 30, 2025 | msn.comH.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PTMay 30, 2025 | insidermonkey.comFY2027 EPS Estimates for Prothena Decreased by HC WainwrightMay 30, 2025 | marketbeat.comWellington Management Group LLP Increases Position in Prothena Co. plc (NASDAQ:PRTA)May 30, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Given Underperform Rating at Bank of AmericaMay 30, 2025 | americanbankingnews.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 30, 2025 | finance.yahoo.comB of A Securities Downgrades Prothena (PRTA)May 29, 2025 | msn.comProthena (NASDAQ:PRTA) Lowered to Underperform Rating by Bank of AmericaMay 29, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Price Target Cut to $81.00 by Analysts at Piper SandlerMay 29, 2025 | americanbankingnews.comProthena (NASDAQ:PRTA) Stock Rating Lowered by OppenheimerMay 29, 2025 | americanbankingnews.comChardan Capital Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock PriceMay 29, 2025 | americanbankingnews.comJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 29, 2025 | finance.yahoo.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 28, 2025 | insidermonkey.comPiper Sandler Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock PriceMay 28, 2025 | marketbeat.comProthena Target of Unusually High Options Trading (NASDAQ:PRTA)May 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRBP, ABVX, MREO, and PRTA Company DescriptionsABIVAX Société Anonyme NASDAQ:ABVX$8.27 +0.53 (+6.85%) As of 09:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Corbus Pharmaceuticals NASDAQ:CRBP$8.32 +0.98 (+13.28%) As of 09:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Mereo BioPharma Group NASDAQ:MREO$2.66 +0.02 (+0.57%) As of 09:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Prothena NASDAQ:PRTA$4.86 +0.20 (+4.29%) As of 09:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
